<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR346.html">Part 346
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 346.22  Permitted combinations of anorectal active ingredients.
                            </h3>
                            <p class="depth1"><em>(a)</em> (2), (4), (6), (7), (8) and (10), and  (b) (2) and (3), provided that the combined percentage by weight of all  protectants in the combination is at least 50 percent of the final  product (e.g., 1 gram of a 2-gram dosage unit). Any protectant  ingredient included in the combination must be present at a level that  contributes at least 12.5 percent by weight (e.g., 0.25 gram of a 2-gram  dosage unit), except cod liver oil and shark liver oil. If an ingredient  in Sec. 346.14(b) is included in the combination, it must not exceed  the concentration limit specified in Sec. 346.14(b).</p><p class="depth1"><em>(b)</em> Any single anorectal ingredient identified in Sec. 346.10,  346.12, 346.16, 346.18, or 346.20 may be combined with up to four  protectants in accordance with paragraph (a) of this section.</p><p class="depth1"><em>(c)</em> Any single local anesthetic identified in Sec. 346.10 may be  combined with any single vasoconstrictor identified in Sec. 346.12.</p><p class="depth1"><em>(d)</em> Any single local anesthetic identified in Sec. 346.10 may be  combined with any single astringent identified in Sec. 346.18.</p><p class="depth1"><em>(e)</em> Any single local anesthetic identified in Sec. 346.10 may be  combined with any single keratolytic identified in Sec. 346.20.</p><p class="depth1"><em>(f)</em> Any single vasoconstrictor identified in Sec. 346.12 may be  combined with any single astringent identified in Sec. 346.18.</p><p class="depth1"><em>(g)</em> Any single analgesic, anesthetic, and antipruritic identified in  Sec. 346.16 may be combined with any single astringent identified in  Sec. 346.18.</p><p class="depth1"><em>(h)</em> Any single analgesic, anesthetic, and antipruritic identified in  Sec. 346.16 may be combined with any single keratolytic identified in  Sec. 346.20.</p><p class="depth2"><em>(i)</em> Any single astringent identified in Sec. 346.18 may be combined  with any single keratolytic identified in Sec. 346.20.</p><p class="depth1"><em>(j)</em> Any single local anesthetic identified in Sec. 346.10 may be  combined with any single vasoconstrictor identified in Sec. 346.12 and  with any single astringent identified in Sec. 346.18.</p><p class="depth1"><em>(k)</em> Any single local anesthetic identified in Sec. 346.10 may be  combined with any single astringent identified in Sec. 346.18 and with  any single keratolytic identified in Sec. 346.20.</p><p class="depth1"><em>(l)</em> Any single vasoconstrictor identified in Sec. 346.12 may be  combined with any single analgesic, anesthetic, and antipruritic  identified in Sec. 346.16 and with any single astringent identified in  Sec. 346.18.</p><p class="depth1"><em>(m)</em> Any single analgesic, anesthetic, and antipruritic identified in  Sec. 346.16 may be combined with any single astringent identified in  Sec. 346.18 and with any single keratolytic identified in Sec. 346.20.</p><p class="depth1"><em>(n)</em> Any combination of ingredients listed in paragraphs (c) through  (m) of this section may be combined with up to four protectants in  accordance with paragraph (a) of this section.</p><p class="depth1"><em>(o)</em> Any product containing calamine for use as a protectant and/or  as an astringent and/or containing zinc oxide for use as a protectant  and/or as an astringent may not have a total weight of zinc oxide  exceeding 25 percent by weight per dosage unit.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
